|
1
|
International Agency for Research on
Cancer and World Health Organization: World Cancer Report 2014.
Stewart BW and Wild C: IARC Press; Lyon: 2014
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arkenau HT: Gastric cancer in the era of
molecularly targeted agents: Current drug development strategies. J
Cancer Res Clin Oncol. 135:855–866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ogino S, Galon J, Fuchs CS and Dranoff G:
Cancer immunology–analysis of host and tumor factors for
personalized medicine. Nat Rev Clin Oncol. 8:711–719. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trinchieri G: Natural killer cells wear
different hats: Effector cells of innate resistance and regulatory
cells of adaptive immunity and of hematopoiesis. Semin Immunol.
7:83–88. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gasser S and Raulet DH: Activation and
self-tolerance of natural killer cells. Immunol Rev. 214:130–142.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anfossi N, André P, Guia S, Falk CS,
Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton
D, et al: Human NK cell education by inhibitory receptors for MHC
class I. Immunity. 25:331–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raulet DH and Guerra N: Oncogenic stress
sensed by the immune system: Role of natural killer cell receptors.
Nat Rev Immunol. 9:568–580. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nausch N and Cerwenka A: NKG2D ligands in
tumor immunity. Oncogene. 27:5944–5958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burgess SJ, Maasho K, Masilamani M,
Narayanan S, Borrego F and Coligan JE: The NKG2D receptor:
Immunobiology and clinical implications. Immunol Res. 40:18–34.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Champsaur M and Lanier LL: Effect of NKG2D
ligand expression on host immune responses. Immunol Rev.
235:267–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez NC, Treiner E, Vance RE,
Jamieson AM, Lemieux S and Raulet DH: A subset of natural killer
cells achieves self-tolerance without expressing inhibitory
receptors specific for self-MHC molecules. Blood. 105:4416–4423.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogasawara K and Lanier LL: NKG2D in NK and
T cell-mediated immunity. J Clin Immunol. 25:534–540. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Diefenbach A, Jamieson AM, Liu SD, Shastri
N and Raulet DH: Ligands for the murine NKG2D receptor: Expression
by tumor cells and activation of NK cells and macrophages. Nat
Immunol. 1:119–126. 2000. View
Article : Google Scholar
|
|
15
|
Duan X, Deng L, Chen X, Lu Y, Zhang Q,
Zhang K, Hu Y, Zeng J and Sun W: Clinical significance of the
immunostimulatory MHC class I chain-related molecule A and NKG2D
receptor on NK cells in pancreatic cancer. Med Oncol. 28:466–474.
2011. View Article : Google Scholar
|
|
16
|
Kohga K, Takehara T, Tatsumi T, Miyagi T,
Ishida H, Ohkawa K, Kanto T, Hiramatsu N and Hayashi N: Anticancer
chemotherapy inhibits MHC class I-related chain a ectodomain
shedding by downregulating ADAM10 expression in hepatocellular
carcinoma. Cancer Res. 69:8050–8057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tamaki S, Sanefuzi N, Kawakami M, Aoki K,
Imai Y, Yamanaka Y, Yamamoto K, Ishitani A, Hatake K and Kirita T:
Association between soluble MICA levels and disease stage IV oral
squamous cell carcinoma in Japanese patients. Hum Immunol.
69:88–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fuertes MB, Girart MV, Molinero LL,
Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA and
Zwirner NW: Intracellular retention of the NKG2D ligand MHC class I
chain-related gene A in human melanomas confers immune privilege
and prevents NK cell-mediated cytotoxicity. J Immunol.
180:4606–4614. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salih HR, Rammensee HG and Steinle A:
Cutting edge: Down-regulation of MICA on human tumors by
proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oppenheim DE, Roberts SJ, Clarke SL,
Filler R, Lewis JM, Tigelaar RE, Girardi M and Hayday AC: Sustained
localized expression of ligand for the activating NKG2D receptor
impairs natural cytotoxicity in vivo and reduces tumor
immunosurveillance. Nat Immunol. 6:928–937. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu JD, Higgins LM, Steinle A, Cosman D,
Haugk K and Plymate SR: Prevalent expression of the
immunostimulatory MHC class I chain-related molecule is
counteracted by shedding in prostate cancer. J Clin Invest.
114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McGilvray RW, Eagle RA, Rolland P,
Jafferji I, Trowsdale J and Durrant LG: ULBP2 and RAET1E NKG2D
ligands are independent predictors of poor prognosis in ovarian
cancer patients. Int J Cancer. 127:1412–1420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Osaki T, Saito H, Yoshikawa T, Matsumoto
S, Tatebe S, Tsujitani S and Ikeguchi M: Decreased NKG2D expression
on CD8+ T cell is involved in immune evasion in patients
with gastric cancer. Clin Cancer Res. 13:382–387. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saito H, Osaki T and Ikeguchi M: Decreased
NKG2D expression on NK cells correlates with impaired NK cell
function in patients with gastric cancer. Gastric Cancer. 15:27–33.
2012. View Article : Google Scholar
|
|
26
|
Kuroda H, Saito H and Ikeguchi M:
Decreased number and reduced NKG2D expression of Vdelta1 gammadelta
T cells are involved in the impaired function of Vdelta1 gammadelta
T cells in the tissue of gastric cancer. Gastric Cancer.
15:433–439. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao S, Wang H, Nie Y, Mi Q, Chen X and
Hou Y: Midkine upregulates MICA/B expression in human gastric
cancer cells and decreases natural killer cell cytotoxicity. Cancer
Immunol Immunother. 61:1745–1753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park SW, Bae JH, Kim SD, Son YO, Kim JY,
Park HJ, Lee CH, Park DY, Kim JY, Lee MK, et al: Comparison of
level of NKG2D ligands between normal and tumor tissue using
multiplex RT-PCR. Cancer Invest. 25:299–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mimura K, Kamiya T, Shiraishi K, Kua LF,
Shabbir A, So J, Yong WP, Suzuki Y, Yoshimoto Y, Nakano T, et al:
Therapeutic potential of highly cytotoxic natural killer cells for
gastric cancer. Int J Cancer. 135:1390–1398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Groh V, Bahram S, Bauer S, Herman A,
Beauchamp M and Spies T: Cell stress-regulated human major
histocompatibility complex class I gene expressed in
gastrointestinal epithelium. Proc Natl Acad Sci USA.
93:12445–12450. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Washington K: 7th edition of the AJCC
cancer staging manual: stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bethke J, Rojas V, Berendsen J, Cárdenas
C, Guzmán F, Gallardo JA and Mercado L: Development of a new
antibody for detecting natural killer enhancing factor (NKEF)-like
protein in infected salmonids. J Fish Dis. 35:379–388. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Santana PA, Álvarez CA, Guzmán F and
Mercado L: Development of a sandwich ELISA for quantifying hepcidin
in Rainbow trout. Fish Shellfish Immunol. 35:748–755. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vogel C and Marcotte EM: Insights into the
regulation of protein abundance from proteomic and transcriptomic
analyses. Nat Rev Genet. 13:227–232. 2012.PubMed/NCBI
|
|
35
|
Zu H, Wang F, Ma Y and Xue Y:
Stage-stratified analysis of prognostic significance of tumor size
in patients with gastric cancer. PLoS One. 8:e545022013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Waldhauer I and Steinle A: NK cells and
cancer immunosurveillance. Oncogene. 27:5932–5943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Raulet DH: Missing self recognition and
self tolerance of natural killer (NK) cells. Semin Immunol.
18:145–150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li K, Mandai M, Hamanishi J, Matsumura N,
Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S and Konishi I:
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in
ovarian cancer: High expression of ULBP2 is an indicator of poor
prognosis. Cancer Immunol Immunother. 58:641–652. 2009. View Article : Google Scholar
|
|
39
|
Paschen A1, Sucker A, Hill B, Moll I,
Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, et
al: Differential clinical significance of individual NKG2D ligands
in melanoma: soluble ULBP2 as an indicator of poor prognosis
superior to S100B. Clin Cancer Res. 15:5208–5215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rebmann V, Schütt P, Brandhorst D, Opalka
B, Moritz T, Nowrousian MR and Grosse-Wilde H: Soluble MICA as an
independent prognostic factor for the overall survival and
progression-free survival of multiple myeloma patients. Clin
Immunol. 123:114–120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe
K, Adachi Y, Yakeishi Y, Matsukuma A and Enjoji M: Pathology and
prognosis of gastric carcinoma. Findings in 10,000 patients who
underwent primary gastrectomy. Cancer. 70:1030–1037. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Siewert JR, Böttcher K, Stein HJ and Roder
JD: Relevant prognostic factors in gastric cancer: Ten-year results
of the German Gastric Cancer Study. Ann Surg. 228:449–461. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Adachi Y, Yasuda K, Inomata M, Sato K,
Shiraishi N and Kitano S: Pathology and prognosis of gastric
carcinoma: Well versus poorly differentiated type. Cancer.
89:1418–1424. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dicken BJ, Bigam DL, Cass C, Mackey JR,
Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and
considerations for future directions. Ann Surg. 241:27–39.
2005.
|
|
45
|
McGilvray RW, Eagle RA, Watson NF,
Al-Attar A, Ball G, Jafferji I, Trowsdale J and Durrant LG: NKG2D
ligand expression in human colorectal cancer reveals associations
with prognosis and evidence for immunoediting. Clin Cancer Res.
15:6993–7002. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang C, Zhou XJ, Li YY, Wan J, Yang LY and
Li GH: Effect of vasoactive intestinal peptide (VIP) on NKG2D
signal pathway and its contribution to immune escape of MKN45
cells. Sci World J. 2013:4295452013.
|
|
47
|
El-Gazzar A, Groh V and Spies T:
Immunobiology and conflicting roles of the human NKG2D lymphocyte
receptor and its ligands in cancer. J Immunol. 191:1509–1515. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee JC, Lee KM, Kim DW and Heo DS:
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies
impaired NK cytotoxicity in cancer patients. J Immunol.
172:7335–7340. 2004. View Article : Google Scholar : PubMed/NCBI
|
